by University College London Credit: Pixabay/CC0 Public Domain Three young patients with relapsed T-cell leukemia have now been treated with base-edited T-cells, as part of a “bench-to-bedside” collaboration between University College London (UCL) and Great Ormond Street Hospital for Children (GOSH). The data from the NHS clinical trial, published in The New England Journal of Medicine, shows...
by American Association for Cancer Research Credit: Unsplash/CC0 Public Domain Posoleucel, an investigational allogeneic off-the-shelf T-cell therapy that simultaneously targets six different viruses, demonstrated promising antiviral efficacy and safety in a phase II study of patients who had undergone stem cell transplantation to treat their cancer or other blood diseases, according to a publication in...
A single leukemia cell, unknowingly engineered with the leukemia-targeting chimeric antigen receptor (CAR) lentivirus and infused back into a patient, was able to reproduce and cause a deadly recurrence of B-cell acute lymphoblastic leukemia (ALL). Newresearch from the Abramson Cancer Center of the University of Pennsylvania found that in one patient, the CAR lentivirus that would usually enter a T cell to teach...
Chimeric antigen receptor (CAR) T-cell therapy has been hailed as one of the great advances in oncology care, but not all patients will respond. This is particularly the case with relapsed/refractory chronic lymphocytic leukemia (CLL), where durable antitumor complete responses have been observed in only 26% of patients, in contrast to the greater than 90%...
Fred Hutchinson Cancer Research Center immunotherapy researchers Drs. Kristin Anderson and Philip Greenberg and their colleagues are working on ways to tweak their team’s early successes with T-cell therapy for leukemia to apply to solid tumors. In a presentation on April 4 at the annual meeting of the American Association of Cancer Research in Washington,...
